HK1200723A1 - 藥學診斷 - Google Patents

藥學診斷

Info

Publication number
HK1200723A1
HK1200723A1 HK15101259.7A HK15101259A HK1200723A1 HK 1200723 A1 HK1200723 A1 HK 1200723A1 HK 15101259 A HK15101259 A HK 15101259A HK 1200723 A1 HK1200723 A1 HK 1200723A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical diagnostic
diagnostic
pharmaceutical
Prior art date
Application number
HK15101259.7A
Other languages
English (en)
Inventor
Pascal Furet
Christine Fritsch
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1200723A1 publication Critical patent/HK1200723A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15101259.7A 2012-03-29 2015-02-05 藥學診斷 HK1200723A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617284P 2012-03-29 2012-03-29
US201361767848P 2013-02-22 2013-02-22
PCT/EP2013/056600 WO2013144249A1 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Publications (1)

Publication Number Publication Date
HK1200723A1 true HK1200723A1 (zh) 2015-08-14

Family

ID=48083130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101259.7A HK1200723A1 (zh) 2012-03-29 2015-02-05 藥學診斷

Country Status (25)

Country Link
US (1) US9795596B2 (zh)
EP (1) EP2830621B1 (zh)
JP (1) JP6224067B2 (zh)
KR (1) KR20140138771A (zh)
CN (1) CN104271136A (zh)
AR (1) AR090544A1 (zh)
AU (1) AU2013241752B2 (zh)
BR (1) BR112014023530A2 (zh)
CA (1) CA2866127A1 (zh)
CL (1) CL2014002576A1 (zh)
CO (1) CO7091176A2 (zh)
EA (1) EA028984B1 (zh)
EC (1) ECSP14025016A (zh)
ES (1) ES2845560T3 (zh)
GT (1) GT201400206A (zh)
HK (1) HK1200723A1 (zh)
IL (1) IL234658B (zh)
IN (1) IN2014DN08970A (zh)
MX (1) MX2014011682A (zh)
NZ (1) NZ628596A (zh)
PH (1) PH12014502168A1 (zh)
SG (2) SG11201405169SA (zh)
TW (1) TW201345525A (zh)
WO (1) WO2013144249A1 (zh)
ZA (1) ZA201405938B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141194A2 (en) * 2013-03-15 2014-09-18 Novartis Ag Biomarker
CA2948351C (en) * 2014-05-09 2023-10-03 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors
MX2017004359A (es) * 2014-10-03 2017-06-23 Novartis Ag Composiciones farmaceuticas que comprenden alpelisib.
WO2017093905A1 (en) * 2015-12-03 2017-06-08 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
WO2019199860A1 (en) * 2018-04-09 2019-10-17 The Research Foundation For The State University Of New York Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JP2846018B2 (ja) 1988-01-21 1999-01-13 ジェネンテク，インコーポレイテッド 核酸配列の増幅および検出
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
ATE138106T1 (de) 1988-07-20 1996-06-15 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8513221B2 (en) 2008-07-07 2013-08-20 Xcovery Holding, LLC PI3K isoform selective inhibitors
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
EA201491787A1 (ru) 2015-01-30
CO7091176A2 (es) 2014-10-21
EA028984B1 (ru) 2018-01-31
US9795596B2 (en) 2017-10-24
WO2013144249A1 (en) 2013-10-03
SG11201405169SA (en) 2014-10-30
CN104271136A (zh) 2015-01-07
CA2866127A1 (en) 2013-10-03
SG10201608001RA (en) 2016-11-29
KR20140138771A (ko) 2014-12-04
JP6224067B2 (ja) 2017-11-01
IL234658B (en) 2018-02-28
ES2845560T3 (es) 2021-07-27
AU2013241752B2 (en) 2016-07-07
EP2830621A1 (en) 2015-02-04
GT201400206A (es) 2017-09-28
ECSP14025016A (es) 2015-09-30
EP2830621B1 (en) 2020-10-21
AU2013241752A1 (en) 2014-09-25
PH12014502168A1 (en) 2014-12-10
NZ628596A (en) 2015-10-30
IN2014DN08970A (zh) 2015-05-22
AR090544A1 (es) 2014-11-19
JP2015514080A (ja) 2015-05-18
CL2014002576A1 (es) 2015-01-23
ZA201405938B (en) 2015-11-25
US20150111927A1 (en) 2015-04-23
TW201345525A (zh) 2013-11-16
MX2014011682A (es) 2015-01-22
BR112014023530A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
IL275998B (en) medical system
EP2852834A4 (en) CLINICAL DIAGNOSTIC SYSTEMS
EP2740430A4 (en) MEDICAL SYSTEM
EP2872028A4 (en) MEDICAL SYSTEM
EP2937110A4 (en) MEDICAL DEVICE
GB2502767B (en) Cannula
EP2679167A4 (en) sonographer
EP2870499A4 (en) DIAGNOSTIC DEVICE
HK1205146A1 (zh) 藥物製劑
GB2500893B (en) Spirometer
GB201205164D0 (en) Pharmaceutical compounds
EP2896349A4 (en) MEDICAL SYSTEM
EP2883547A4 (en) MEDICINE
HK1200723A1 (zh) 藥學診斷
HK1215789A1 (zh) 藥物組合
EP2921123A4 (en) MEDICAL DEVICE
GB2500241B (en) Medical device
HK1216619A1 (zh) 藥物化合物
GB201215502D0 (en) Medical use
GB2501576B (en) Medical device
GB201317825D0 (en) Medical device
EP2740398A4 (en) MEDICAL SYSTEM
GB201202027D0 (en) Pharmaceutical compounds
GB201212442D0 (en) Medical device
GB201219236D0 (en) Pharmaceutical compounds